APO Research
Talk to an analyst

APO RESEARCH · REPORT

Irbesartan

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Irbesartan Market Outlook and Growth Opportunities 2026

30 December 2025215 pages

Choose your research edition.

Industry ResearchIrbesartan Industry Research Report 2026147 pages · $2,950 USDIndustry Growth & TrendsGlobal Irbesartan Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal Irbesartan Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Irbesartan Market Outlook and Growth Opportunities 2026215 pages · $4,250 USDMarket Analysis & ForecastGlobal Irbesartan Market Analysis and Forecast 2026-2032211 pages · $4,950 USD

Market perspective

The global Irbesartan market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Irbesartan is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Irbesartan is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Irbesartan is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Irbesartan market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Irbesartan market include Angita Pharma, Apotex, Auro Pharma, Avanstra, BMS, Hanall, Shionogi, Sumitomo Dainippon Pharma and Taj Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Irbesartan market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Irbesartan and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Irbesartan sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Irbesartan market size, projected growth trends, production technologies, key applications, and end-use industries.

Irbesartan Segment by Company

Angita Pharma

Apotex

Auro Pharma

Avanstra

BMS

Hanall

Shionogi

Sumitomo Dainippon Pharma

Taj Pharmaceuticals

Verdant Life Sciences

Jiangsu Hengrui Medicine

Jiangsu Wangao Pharmaceutical

CTTQ

Novartis

Sanofi

Teva

Tianjin Huairen Pharmaceutical

Xiansheng Pharmaceutical

Yuanhe Pharmaceutical

Zhejiang Ainuo Pharmaceutical

Zhejiang Huahai Pharmaceutical

Zhuhai Rundu Pharma

Irbesartan Segment by Type

Combination Drugs

Prescribed Drugs

Irbesartan Segment by Application

Heart Failure

Fibrous Fibrillation

Kidney Disease

Hyperlipidemia

High Blood Pressure

Other

Irbesartan Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Irbesartan status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Irbesartan market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Irbesartan significant trends, drivers, influence factors in global and regions.

6. To analyze Irbesartan competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Irbesartan market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Irbesartan and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Irbesartan.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Irbesartan market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Irbesartan industry.

Chapter 3: Detailed analysis of Irbesartan manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Irbesartan in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Irbesartan in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Irbesartan Industry Trends Table 2. Irbesartan Industry Drivers Table 3. Irbesartan Industry Opportunities and Challenges Table 4. Irbesartan Industry Restraints Table 5. Global Irbesartan Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Irbesartan Revenue Share by Company (2021-2026) Table 7. Global Irbesartan Sales Volume by Company (Kg) & (2021-2026) Table 8. Global Irbesartan Sales Volume Share by Company (2021-2026) Table 9. Global Irbesartan Average Price (US$/Kg) of Company (2021-2026) Table 10. Global Irbesartan Company Ranking, (2024-2026) & (USD Million) Table 11. Global Irbesartan Key Company Manufacturing Base & Headquarters Table 12. Global Irbesartan Company, Product Type & Application Table 13. Global Irbesartan Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Irbesartan by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Combination Drugs Table 18. Significant Companies of Prescribed Drugs Table 19. Global Irbesartan Sales Volume by Type 2021 VS 2025 VS 2032 (Kg) Table 20. Global Irbesartan Sales Volume by Type (2021-2026) & (Kg) Table 21. Global Irbesartan Sales Volume by Type (2027-2032) & (Kg) Table 22. Global Irbesartan Sales Volume Share by Type (2021-2026) Table 23. Global Irbesartan Sales Volume Share by Type (2027-2032) Table 24. Global Irbesartan Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Irbesartan Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Irbesartan Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Irbesartan Sales Value Share by Type (2021-2026) Table 28. Global Irbesartan Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Heart Failure Table 30. Significant Companies of Fibrous Fibrillation Table 31. Significant Companies of Kidney Disease Table 32. Significant Companies of Hyperlipidemia Table 33. Significant Companies of High Blood Pressure Table 34. Significant Companies of Other Table 35. Global Irbesartan Sales Volume by Application 2021 VS 2025 VS 2032 (Kg) Table 36. Global Irbesartan Sales Volume by Application (2021-2026) & (Kg) Table 37. Global Irbesartan Sales Volume by Application (2027-2032) & (Kg) Table 38. Global Irbesartan Sales Volume Share by Application (2021-2026) Table 39. Global Irbesartan Sales Volume Share by Application (2027-2032) Table 40. Global Irbesartan Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Irbesartan Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Irbesartan Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Irbesartan Sales Value Share by Application (2021-2026) Table 44. Global Irbesartan Sales Value Share by Application (2027-2032) Table 45. Global Irbesartan Sales by Region: 2021 VS 2025 VS 2032 (Kg) Table 46. Global Irbesartan Sales by Region (2021-2026) & (Kg) Table 47. Global Irbesartan Sales Market Share by Region (2021-2026) Table 48. Global Irbesartan Sales by Region (2027-2032) & (Kg) Table 49. Global Irbesartan Sales Market Share by Region (2027-2032) Table 50. Global Irbesartan Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Irbesartan Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Irbesartan Sales Value Share by Region (2021-2026) Table 53. Global Irbesartan Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Irbesartan Sales Value Share by Region (2027-2032) Table 55. Global Irbesartan Market Average Price (US$/Kg) by Region (2021-2026) Table 56. Global Irbesartan Market Average Price (US$/Kg) by Region (2027-2032) Table 57. Global Irbesartan Sales by Country: 2021 VS 2025 VS 2032 (Kg) Table 58. Global Irbesartan Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Irbesartan Sales by Country (2021-2026) & (Kg) Table 60. Global Irbesartan Sales Market Share by Country (2021-2026) Table 61. Global Irbesartan Sales by Country (2027-2032) & (Kg) Table 62. Global Irbesartan Sales Market Share by Country (2027-2032) Table 63. Global Irbesartan Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Irbesartan Sales Value Market Share by Country (2021-2026) Table 65. Global Irbesartan Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Irbesartan Sales Value Market Share by Country (2027-2032) Table 67. Angita Pharma Company Information Table 68. Angita Pharma Business Overview Table 69. Angita Pharma Irbesartan Sales (Kg), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 70. Angita Pharma Irbesartan Product Portfolio Table 71. Angita Pharma Recent Development Table 72. Apotex Company Information Table 73. Apotex Business Overview Table 74. Apotex Irbesartan Sales (Kg), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 75. Apotex Irbesartan Product Portfolio Table 76. Apotex Recent Development Table 77. Auro Pharma Company Information Table 78. Auro Pharma Business Overview Table 79. Auro Pharma Irbesartan Sales (Kg), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 80. Auro Pharma Irbesartan Product Portfolio Table 81. Auro Pharma Recent Development Table 82. Avanstra Company Information Table 83. Avanstra Business Overview Table 84. Avanstra Irbesartan Sales (Kg), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 85. Avanstra Irbesartan Product Portfolio Table 86. Avanstra Recent Development Table 87. BMS Company Information Table 88. BMS Business Overview Table 89. BMS Irbesartan Sales (Kg), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 90. BMS Irbesartan Product Portfolio Table 91. BMS Recent Development Table 92. Hanall Company Information Table 93. Hanall Business Overview Table 94. Hanall Irbesartan Sales (Kg), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 95. Hanall Irbesartan Product Portfolio Table 96. Hanall Recent Development Table 97. Shionogi Company Information Table 98. Shionogi Business Overview Table 99. Shionogi Irbesartan Sales (Kg), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 100. Shionogi Irbesartan Product Portfolio Table 101. Shionogi Recent Development Table 102. Sumitomo Dainippon Pharma Company Information Table 103. Sumitomo Dainippon Pharma Business Overview Table 104. Sumitomo Dainippon Pharma Irbesartan Sales (Kg), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 105. Sumitomo Dainippon Pharma Irbesartan Product Portfolio Table 106. Sumitomo Dainippon Pharma Recent Development Table 107. Taj Pharmaceuticals Company Information Table 108. Taj Pharmaceuticals Business Overview Table 109. Taj Pharmaceuticals Irbesartan Sales (Kg), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 110. Taj Pharmaceuticals Irbesartan Product Portfolio Table 111. Taj Pharmaceuticals Recent Development Table 112. Verdant Life Sciences Company Information Table 113. Verdant Life Sciences Business Overview Table 114. Verdant Life Sciences Irbesartan Sales (Kg), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 115. Verdant Life Sciences Irbesartan Product Portfolio Table 116. Verdant Life Sciences Recent Development Table 117. Jiangsu Hengrui Medicine Company Information Table 118. Jiangsu Hengrui Medicine Business Overview Table 119. Jiangsu Hengrui Medicine Irbesartan Sales (Kg), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 120. Jiangsu Hengrui Medicine Irbesartan Product Portfolio Table 121. Jiangsu Hengrui Medicine Recent Development Table 122. Jiangsu Wangao Pharmaceutical Company Information Table 123. Jiangsu Wangao Pharmaceutical Business Overview Table 124. Jiangsu Wangao Pharmaceutical Irbesartan Sales (Kg), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 125. Jiangsu Wangao Pharmaceutical Irbesartan Product Portfolio Table 126. Jiangsu Wangao Pharmaceutical Recent Development Table 127. CTTQ Company Information Table 128. CTTQ Business Overview Table 129. CTTQ Irbesartan Sales (Kg), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 130. CTTQ Irbesartan Product Portfolio Table 131. CTTQ Recent Development Table 132. Novartis Company Information Table 133. Novartis Business Overview Table 134. Novartis Irbesartan Sales (Kg), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 135. Novartis Irbesartan Product Portfolio Table 136. Novartis Recent Development Table 137. Sanofi Company Information Table 138. Sanofi Business Overview Table 139. Sanofi Irbesartan Sales (Kg), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 140. Sanofi Irbesartan Product Portfolio Table 141. Sanofi Recent Development Table 142. Teva Company Information Table 143. Teva Business Overview Table 144. Teva Irbesartan Sales (Kg), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 145. Teva Irbesartan Product Portfolio Table 146. Teva Recent Development Table 147. Tianjin Huairen Pharmaceutical Company Information Table 148. Tianjin Huairen Pharmaceutical Business Overview Table 149. Tianjin Huairen Pharmaceutical Irbesartan Sales (Kg), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 150. Tianjin Huairen Pharmaceutical Irbesartan Product Portfolio Table 151. Tianjin Huairen Pharmaceutical Recent Development Table 152. Xiansheng Pharmaceutical Company Information Table 153. Xiansheng Pharmaceutical Business Overview Table 154. Xiansheng Pharmaceutical Irbesartan Sales (Kg), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 155. Xiansheng Pharmaceutical Irbesartan Product Portfolio Table 156. Xiansheng Pharmaceutical Recent Development Table 157. Yuanhe Pharmaceutical Company Information Table 158. Yuanhe Pharmaceutical Business Overview Table 159. Yuanhe Pharmaceutical Irbesartan Sales (Kg), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 160. Yuanhe Pharmaceutical Irbesartan Product Portfolio Table 161. Yuanhe Pharmaceutical Recent Development Table 162. Zhejiang Ainuo Pharmaceutical Company Information Table 163. Zhejiang Ainuo Pharmaceutical Business Overview Table 164. Zhejiang Ainuo Pharmaceutical Irbesartan Sales (Kg), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 165. Zhejiang Ainuo Pharmaceutical Irbesartan Product Portfolio Table 166. Zhejiang Ainuo Pharmaceutical Recent Development Table 167. Zhejiang Huahai Pharmaceutical Company Information Table 168. Zhejiang Huahai Pharmaceutical Business Overview Table 169. Zhejiang Huahai Pharmaceutical Irbesartan Sales (Kg), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 170. Zhejiang Huahai Pharmaceutical Irbesartan Product Portfolio Table 171. Zhejiang Huahai Pharmaceutical Recent Development Table 172. Zhuhai Rundu Pharma Company Information Table 173. Zhuhai Rundu Pharma Business Overview Table 174. Zhuhai Rundu Pharma Irbesartan Sales (Kg), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 175. Zhuhai Rundu Pharma Irbesartan Product Portfolio Table 176. Zhuhai Rundu Pharma Recent Development Table 177. Key Raw Materials Table 178. Raw Materials Key Suppliers Table 179. Irbesartan Distributors List Table 180. Irbesartan Customers List Table 181. Research Programs/Design for This Report Table 182. Authors List of This Report Table 183. Secondary Sources Table 184. Primary Sources List of Figures Figure 1. Irbesartan Product Image Figure 2. Global Irbesartan Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Irbesartan Sales Value (2021-2032) & (US$ Million) Figure 4. Global Irbesartan Sales (2021-2032) & (Kg) Figure 5. Global Irbesartan Sales Average Price (US$/Kg) & (2021-2032) Figure 6. Global Irbesartan Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Combination Drugs Image Figure 10. Prescribed Drugs Image Figure 11. Global Irbesartan Sales Volume by Type (2021 VS 2025 VS 2032) & (Kg) Figure 12. Global Irbesartan Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Irbesartan Sales Volume Share by Type (2021-2032) Figure 14. Global Irbesartan Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Irbesartan Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Irbesartan Sales Value Share by Type (2021-2032) Figure 17. Heart Failure Image Figure 18. Fibrous Fibrillation Image Figure 19. Kidney Disease Image Figure 20. Hyperlipidemia Image Figure 21. High Blood Pressure Image Figure 22. Other Image Figure 23. Global Irbesartan Sales Volume by Application (2021 VS 2025 VS 2032) & (Kg) Figure 24. Global Irbesartan Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Irbesartan Sales Volume Share by Application (2021-2032) Figure 26. Global Irbesartan Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Irbesartan Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Irbesartan Sales Value Share by Application (2021-2032) Figure 29. Global Irbesartan Sales by Region: 2021 VS 2025 VS 2032 (Kg) Figure 30. Global Irbesartan Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Irbesartan Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Irbesartan Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Irbesartan Sales Value (2021-2032) & (US$ Million) Figure 34. North America Irbesartan Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Irbesartan Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Irbesartan Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Irbesartan Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Irbesartan Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Irbesartan Sales Value (2021-2032) & (US$ Million) Figure 40. South America Irbesartan Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Irbesartan Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Irbesartan Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Irbesartan Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Irbesartan Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Irbesartan Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Irbesartan Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Irbesartan Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Irbesartan Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Irbesartan Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Irbesartan Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Irbesartan Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Irbesartan Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Irbesartan Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Irbesartan Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Irbesartan Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Irbesartan Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Irbesartan Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Irbesartan Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Irbesartan Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Irbesartan Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Irbesartan Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Irbesartan Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Irbesartan Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Irbesartan Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Irbesartan Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Irbesartan Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Irbesartan Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Irbesartan Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Irbesartan Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Irbesartan Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Irbesartan Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Irbesartan Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Irbesartan Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Irbesartan Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Irbesartan Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Irbesartan Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Irbesartan Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Irbesartan Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Irbesartan Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Irbesartan Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Irbesartan Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Irbesartan Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Irbesartan Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Irbesartan Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Irbesartan Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Irbesartan Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Irbesartan Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Irbesartan Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Irbesartan Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Irbesartan Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Irbesartan Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Irbesartan Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Irbesartan Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Irbesartan Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Irbesartan Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Irbesartan Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Irbesartan Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Irbesartan Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Irbesartan Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Irbesartan Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Irbesartan Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Irbesartan Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Irbesartan Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Irbesartan Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Irbesartan Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Irbesartan Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Irbesartan Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Irbesartan Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Irbesartan Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Irbesartan Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Irbesartan Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Irbesartan Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Irbesartan Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Irbesartan Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Irbesartan Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Irbesartan Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Irbesartan Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Irbesartan Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Irbesartan Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Irbesartan Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Irbesartan Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Irbesartan Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Irbesartan Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Irbesartan Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Irbesartan Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Irbesartan Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Irbesartan Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Irbesartan Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Combination Drugs
  • Prescribed Drugs
Applications
  • Heart Failure
  • Fibrous Fibrillation
  • Kidney Disease
  • Hyperlipidemia
  • High Blood Pressure
  • Other
Companies covered
  • Angita Pharma
  • Apotex
  • Auro Pharma
  • Avanstra
  • BMS
  • Hanall
  • Shionogi
  • Sumitomo Dainippon Pharma
  • Taj Pharmaceuticals
  • Verdant Life Sciences
  • Jiangsu Hengrui Medicine
  • Jiangsu Wangao Pharmaceutical
  • CTTQ
  • Novartis
  • Sanofi
  • Teva
  • Tianjin Huairen Pharmaceutical
  • Xiansheng Pharmaceutical
  • Yuanhe Pharmaceutical
  • Zhejiang Ainuo Pharmaceutical
  • Zhejiang Huahai Pharmaceutical
  • Zhuhai Rundu Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Irbesartan Sales Value (2021-2032)
  4. 1.2.2 Global Irbesartan Sales Volume (2021-2032)
  5. 1.2.3 Global Irbesartan Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Irbesartan Market Dynamics
  1. 2.1 Irbesartan Industry Trends
  2. 2.2 Irbesartan Industry Drivers
  3. 2.3 Irbesartan Industry Opportunities and Challenges
  4. 2.4 Irbesartan Industry Restraints
3 Irbesartan Market by Company
  1. 3.1 Global Irbesartan Company Revenue Ranking in 2025
  2. 3.2 Global Irbesartan Revenue by Company (2021-2026)
  3. 3.3 Global Irbesartan Sales Volume by Company (2021-2026)
  4. 3.4 Global Irbesartan Average Price by Company (2021-2026)
  5. 3.5 Global Irbesartan Company Ranking (2024-2026)
  6. 3.6 Global Irbesartan Company Manufacturing Base and Headquarters
  7. 3.7 Global Irbesartan Company Product Type and Application
  8. 3.8 Global Irbesartan Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Irbesartan Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Irbesartan Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Irbesartan Market by Type
  1. 4.1 Irbesartan Type Introduction
  2. 4.1.1 Combination Drugs
  3. 4.1.2 Prescribed Drugs
  4. 4.2 Global Irbesartan Sales Volume by Type
  5. 4.2.1 Global Irbesartan Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Irbesartan Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Irbesartan Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Irbesartan Sales Value by Type
  9. 4.3.1 Global Irbesartan Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Irbesartan Sales Value by Type (2021-2032)
  11. 4.3.3 Global Irbesartan Sales Value Share by Type (2021-2032)
5 Irbesartan Market by Application
  1. 5.1 Irbesartan Application Introduction
  2. 5.1.1 Heart Failure
  3. 5.1.2 Fibrous Fibrillation
  4. 5.1.3 Kidney Disease
  5. 5.1.4 Hyperlipidemia
  6. 5.1.5 High Blood Pressure
  7. 5.1.6 Other
  8. 5.2 Global Irbesartan Sales Volume by Application
  9. 5.2.1 Global Irbesartan Sales Volume by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global Irbesartan Sales Volume by Application (2021-2032)
  11. 5.2.3 Global Irbesartan Sales Volume Share by Application (2021-2032)
  12. 5.3 Global Irbesartan Sales Value by Application
  13. 5.3.1 Global Irbesartan Sales Value by Application (2021 VS 2025 VS 2032)
  14. 5.3.2 Global Irbesartan Sales Value by Application (2021-2032)
  15. 5.3.3 Global Irbesartan Sales Value Share by Application (2021-2032)
6 Irbesartan Regional Sales and Value Analysis
  1. 6.1 Global Irbesartan Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Irbesartan Sales by Region (2021-2032)
  3. 6.2.1 Global Irbesartan Sales by Region: 2021-2026
  4. 6.2.2 Global Irbesartan Sales by Region (2027-2032)
  5. 6.3 Global Irbesartan Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Irbesartan Sales Value by Region (2021-2032)
  7. 6.4.1 Global Irbesartan Sales Value by Region: 2021-2026
  8. 6.4.2 Global Irbesartan Sales Value by Region (2027-2032)
  9. 6.5 Global Irbesartan Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Irbesartan Sales Value (2021-2032)
  12. 6.6.2 North America Irbesartan Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Irbesartan Sales Value (2021-2032)
  15. 6.7.2 Europe Irbesartan Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Irbesartan Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Irbesartan Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Irbesartan Sales Value (2021-2032)
  21. 6.9.2 South America Irbesartan Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Irbesartan Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Irbesartan Sales Value Share by Country, 2025 VS 2032
7 Irbesartan Country-level Sales and Value Analysis
  1. 7.1 Global Irbesartan Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Irbesartan Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Irbesartan Sales by Country (2021-2032)
  4. 7.3.1 Global Irbesartan Sales by Country (2021-2026)
  5. 7.3.2 Global Irbesartan Sales by Country (2027-2032)
  6. 7.4 Global Irbesartan Sales Value by Country (2021-2032)
  7. 7.4.1 Global Irbesartan Sales Value by Country (2021-2026)
  8. 7.4.2 Global Irbesartan Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Irbesartan Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Irbesartan Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Irbesartan Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Irbesartan Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Irbesartan Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Irbesartan Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Irbesartan Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Irbesartan Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Irbesartan Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Irbesartan Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Irbesartan Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Irbesartan Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Irbesartan Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Irbesartan Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Irbesartan Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Irbesartan Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Irbesartan Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Irbesartan Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Irbesartan Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Irbesartan Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Irbesartan Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Irbesartan Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Irbesartan Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Irbesartan Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Irbesartan Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Irbesartan Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Irbesartan Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Irbesartan Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Irbesartan Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Irbesartan Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Irbesartan Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Irbesartan Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Irbesartan Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Irbesartan Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Irbesartan Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Irbesartan Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Irbesartan Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Irbesartan Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Irbesartan Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Irbesartan Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Irbesartan Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Irbesartan Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Irbesartan Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Irbesartan Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Irbesartan Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Irbesartan Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Irbesartan Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Irbesartan Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Irbesartan Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Irbesartan Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Irbesartan Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Irbesartan Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Irbesartan Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Irbesartan Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Irbesartan Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Irbesartan Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Irbesartan Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Irbesartan Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Irbesartan Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Irbesartan Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Irbesartan Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Irbesartan Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Irbesartan Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Irbesartan Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Irbesartan Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Irbesartan Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Irbesartan Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Irbesartan Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Irbesartan Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Irbesartan Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Irbesartan Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Irbesartan Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Irbesartan Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Irbesartan Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Irbesartan Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Irbesartan Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Irbesartan Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Irbesartan Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Irbesartan Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Irbesartan Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Irbesartan Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Irbesartan Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Irbesartan Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Irbesartan Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Angita Pharma
  2. 8.1.1 Angita Pharma Company Information
  3. 8.1.2 Angita Pharma Business Overview
  4. 8.1.3 Angita Pharma Irbesartan Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Angita Pharma Irbesartan Product Portfolio
  6. 8.1.5 Angita Pharma Recent Developments
  7. 8.2 Apotex
  8. 8.2.1 Apotex Company Information
  9. 8.2.2 Apotex Business Overview
  10. 8.2.3 Apotex Irbesartan Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Apotex Irbesartan Product Portfolio
  12. 8.2.5 Apotex Recent Developments
  13. 8.3 Auro Pharma
  14. 8.3.1 Auro Pharma Company Information
  15. 8.3.2 Auro Pharma Business Overview
  16. 8.3.3 Auro Pharma Irbesartan Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Auro Pharma Irbesartan Product Portfolio
  18. 8.3.5 Auro Pharma Recent Developments
  19. 8.4 Avanstra
  20. 8.4.1 Avanstra Company Information
  21. 8.4.2 Avanstra Business Overview
  22. 8.4.3 Avanstra Irbesartan Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Avanstra Irbesartan Product Portfolio
  24. 8.4.5 Avanstra Recent Developments
  25. 8.5 BMS
  26. 8.5.1 BMS Company Information
  27. 8.5.2 BMS Business Overview
  28. 8.5.3 BMS Irbesartan Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 BMS Irbesartan Product Portfolio
  30. 8.5.5 BMS Recent Developments
  31. 8.6 Hanall
  32. 8.6.1 Hanall Company Information
  33. 8.6.2 Hanall Business Overview
  34. 8.6.3 Hanall Irbesartan Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Hanall Irbesartan Product Portfolio
  36. 8.6.5 Hanall Recent Developments
  37. 8.7 Shionogi
  38. 8.7.1 Shionogi Company Information
  39. 8.7.2 Shionogi Business Overview
  40. 8.7.3 Shionogi Irbesartan Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Shionogi Irbesartan Product Portfolio
  42. 8.7.5 Shionogi Recent Developments
  43. 8.8 Sumitomo Dainippon Pharma
  44. 8.8.1 Sumitomo Dainippon Pharma Company Information
  45. 8.8.2 Sumitomo Dainippon Pharma Business Overview
  46. 8.8.3 Sumitomo Dainippon Pharma Irbesartan Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Sumitomo Dainippon Pharma Irbesartan Product Portfolio
  48. 8.8.5 Sumitomo Dainippon Pharma Recent Developments
  49. 8.9 Taj Pharmaceuticals
  50. 8.9.1 Taj Pharmaceuticals Company Information
  51. 8.9.2 Taj Pharmaceuticals Business Overview
  52. 8.9.3 Taj Pharmaceuticals Irbesartan Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Taj Pharmaceuticals Irbesartan Product Portfolio
  54. 8.9.5 Taj Pharmaceuticals Recent Developments
  55. 8.10 Verdant Life Sciences
  56. 8.10.1 Verdant Life Sciences Company Information
  57. 8.10.2 Verdant Life Sciences Business Overview
  58. 8.10.3 Verdant Life Sciences Irbesartan Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Verdant Life Sciences Irbesartan Product Portfolio
  60. 8.10.5 Verdant Life Sciences Recent Developments
  61. 8.11 Jiangsu Hengrui Medicine
  62. 8.11.1 Jiangsu Hengrui Medicine Company Information
  63. 8.11.2 Jiangsu Hengrui Medicine Business Overview
  64. 8.11.3 Jiangsu Hengrui Medicine Irbesartan Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Jiangsu Hengrui Medicine Irbesartan Product Portfolio
  66. 8.11.5 Jiangsu Hengrui Medicine Recent Developments
  67. 8.12 Jiangsu Wangao Pharmaceutical
  68. 8.12.1 Jiangsu Wangao Pharmaceutical Company Information
  69. 8.12.2 Jiangsu Wangao Pharmaceutical Business Overview
  70. 8.12.3 Jiangsu Wangao Pharmaceutical Irbesartan Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Jiangsu Wangao Pharmaceutical Irbesartan Product Portfolio
  72. 8.12.5 Jiangsu Wangao Pharmaceutical Recent Developments
  73. 8.13 CTTQ
  74. 8.13.1 CTTQ Company Information
  75. 8.13.2 CTTQ Business Overview
  76. 8.13.3 CTTQ Irbesartan Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 CTTQ Irbesartan Product Portfolio
  78. 8.13.5 CTTQ Recent Developments
  79. 8.14 Novartis
  80. 8.14.1 Novartis Company Information
  81. 8.14.2 Novartis Business Overview
  82. 8.14.3 Novartis Irbesartan Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Novartis Irbesartan Product Portfolio
  84. 8.14.5 Novartis Recent Developments
  85. 8.15 Sanofi
  86. 8.15.1 Sanofi Company Information
  87. 8.15.2 Sanofi Business Overview
  88. 8.15.3 Sanofi Irbesartan Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Sanofi Irbesartan Product Portfolio
  90. 8.15.5 Sanofi Recent Developments
  91. 8.16 Teva
  92. 8.16.1 Teva Company Information
  93. 8.16.2 Teva Business Overview
  94. 8.16.3 Teva Irbesartan Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Teva Irbesartan Product Portfolio
  96. 8.16.5 Teva Recent Developments
  97. 8.17 Tianjin Huairen Pharmaceutical
  98. 8.17.1 Tianjin Huairen Pharmaceutical Company Information
  99. 8.17.2 Tianjin Huairen Pharmaceutical Business Overview
  100. 8.17.3 Tianjin Huairen Pharmaceutical Irbesartan Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Tianjin Huairen Pharmaceutical Irbesartan Product Portfolio
  102. 8.17.5 Tianjin Huairen Pharmaceutical Recent Developments
  103. 8.18 Xiansheng Pharmaceutical
  104. 8.18.1 Xiansheng Pharmaceutical Company Information
  105. 8.18.2 Xiansheng Pharmaceutical Business Overview
  106. 8.18.3 Xiansheng Pharmaceutical Irbesartan Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Xiansheng Pharmaceutical Irbesartan Product Portfolio
  108. 8.18.5 Xiansheng Pharmaceutical Recent Developments
  109. 8.19 Yuanhe Pharmaceutical
  110. 8.19.1 Yuanhe Pharmaceutical Company Information
  111. 8.19.2 Yuanhe Pharmaceutical Business Overview
  112. 8.19.3 Yuanhe Pharmaceutical Irbesartan Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Yuanhe Pharmaceutical Irbesartan Product Portfolio
  114. 8.19.5 Yuanhe Pharmaceutical Recent Developments
  115. 8.20 Zhejiang Ainuo Pharmaceutical
  116. 8.20.1 Zhejiang Ainuo Pharmaceutical Company Information
  117. 8.20.2 Zhejiang Ainuo Pharmaceutical Business Overview
  118. 8.20.3 Zhejiang Ainuo Pharmaceutical Irbesartan Sales, Value and Gross Margin (2021-2026)
  119. 8.20.4 Zhejiang Ainuo Pharmaceutical Irbesartan Product Portfolio
  120. 8.20.5 Zhejiang Ainuo Pharmaceutical Recent Developments
  121. 8.21 Zhejiang Huahai Pharmaceutical
  122. 8.21.1 Zhejiang Huahai Pharmaceutical Company Information
  123. 8.21.2 Zhejiang Huahai Pharmaceutical Business Overview
  124. 8.21.3 Zhejiang Huahai Pharmaceutical Irbesartan Sales, Value and Gross Margin (2021-2026)
  125. 8.21.4 Zhejiang Huahai Pharmaceutical Irbesartan Product Portfolio
  126. 8.21.5 Zhejiang Huahai Pharmaceutical Recent Developments
  127. 8.22 Zhuhai Rundu Pharma
  128. 8.22.1 Zhuhai Rundu Pharma Company Information
  129. 8.22.2 Zhuhai Rundu Pharma Business Overview
  130. 8.22.3 Zhuhai Rundu Pharma Irbesartan Sales, Value and Gross Margin (2021-2026)
  131. 8.22.4 Zhuhai Rundu Pharma Irbesartan Product Portfolio
  132. 8.22.5 Zhuhai Rundu Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Irbesartan Value Chain Analysis
  2. 9.1.1 Irbesartan Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Irbesartan Sales Mode & Process
  6. 9.2 Irbesartan Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Irbesartan Distributors
  9. 9.2.3 Irbesartan Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst